1. Medtech Insight

US FDA Ready To Accept 510(k) Devices To Expedited Access/Breakthrough Pathway

 
• By Elizabeth Orr

Manufacturers considering the Expedited Access Pathway for 510(k) devices should start the submission process, experts and agency staff say, although it still remains to be seen what types of 510(k) devices will qualify. The December-enacted 21st Century Cures Act added 510(k) devices to the program as part of its Breakthrough Device provision.

MT1705_Business-Opportunity_544079215-_1200x675

FDA is ready to implement a clause in the 21st Century Cures Act that requires the agency to accept 510(k) devices into the Expedited Access Pathway (EAP) for breakthrough devices, agency staff says. What types of 510(k) devices might qualify for the program in practice remains to be seen, but experts suggest devices that offer significant benefits to patients, even if not completely new, may be the most likely participants.

Introduced by FDA in 2015, EAP offers a faster development path to market for some devices that significantly improve treatment for an unaddressed debilitating or life-threatening disease or condition. The...

More from Regulation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 
• By Amanda Maxwell

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.